ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first patient in (FPI) for a Phase Ib clinical study of its dual-target macromolecular drug amulirafusp alfa (IMM0306) in the treatment of moderate to severe systemic lupus erythematosus (SLE). This marks a significant advancement in the clinical evaluation of this innovative therapy.
IMM0306 is a bispecific antibody (BsAb) that targets cluster of differentiation 47 (CD47) and CD20, making it the first drug of its kind to enter clinical evaluation globally. This drug enhances antibody-dependent cell phagocytosis (ADCP) and antibody-dependent cytotoxicity (ADCC), allowing it to simultaneously bind to CD47 and CD20 expressed on malignant B cells. With a higher affinity for CD20 than CD47, IMM0306 has the potential to significantly improve therapeutic efficacy in treating SLE.- Flcube.com
